LEXINGTON, Mass., Dec. 2, 2021 /PRNewswire/ -- iSpecimen
Inc. (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online
marketplace for human biospecimens, today announced it has
recently expanded its global biospecimen provider network in
support of research related to neurological disorders, which
afflict around one billion people worldwide, or an estimated 1 in 6
In the past 10 months, iSpecimen has added more than a dozen
sample providers to its network of suppliers that provide access to
banked or custom collections of biospecimens such as cerebrospinal
fluid, other biofluids, or cells to help advance CNS research.
Neurological disorders include
amyotrophic lateral sclerosis (or ALS), Alzheimer's disease,
Parkinson's disease, and stroke. Also, some COVID-19 patients
report neurological symptoms such as muscle aches, headaches, and
loss of taste or smell. iSpecimen's capabilities include providing
specially collected samples from patients who have been infected
with the SARS-CoV-2 virus, which causes COVID-19, and who exhibit
These are among a wide range of human tissue, biofluids, and
hematopoietic stem and immune cells to which iSpecimen provides
access through the iSpecimen Marketplace. Such access is essential
since researchers have otherwise been forced to scale back their
work due to difficulties procuring sufficient numbers of
iSpecimen's announcement of its expanded supplier network comes
less than a week after the U.S. wrapped up National Epilepsy
Awareness Month and National Alzheimer's Disease Awareness Month.
"Neurological disorders are prevalent, varied, and complicated, and
we are committed to doing everything we can to support researchers
as they work every day to develop treatments, diagnostics, and
cures for these conditions," said iSpecimen Founder and CEO,
Christopher Ianelli, MD, Ph.D.
Streamlining Biospecimen Procurement
the Office of Biorepositories and Biospecimen Research reported in
2011 and iSpecimen's survey of researchers performed in 2019
indicate that 4 in 5 researchers have limited the scope of their
work due to the shortage of quality biospecimens. To address this
challenge and accelerate scientific discovery, the iSpecimen
Marketplace connects life science researchers who need
biospecimens with patients and healthcare organizations that
can provide them. The iSpecimen Marketplace automates search,
selection, contracting, compliance/ethics (institutional review
board) audits, quoting, order management, invoicing, and more.
iSpecimen offers an online marketplace
for human biospecimens, connecting life scientists in commercial
and non-profit organizations with healthcare providers that have
access to patients and specimens needed for medical discovery.
Proprietary, cloud-based technology enables scientists to
intuitively search for specimens and patients across a federated
partner network of hospitals, labs, biobanks, blood centers, and
other healthcare organizations. For more information about
iSpecimen, please visit www.ispecimen.com.
This press release may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Such
forward-looking statements are characterized by future or
conditional verbs such as "may," "will," "expect," "intend,"
"anticipate," believe," "estimate" and "continue" or similar words.
You should read statements that contain these words carefully
because they discuss future expectations and plans, which contain
projections of future results of operations or financial condition
or state other forward-looking information.
Forward-looking statements are predictions, projections and
other statements about future events that are based on current
expectations and assumptions and, as a result, are subject to risks
and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this press
release, including but not limited to the risk factors contained in
the Company's filings with the Securities and Exchange Commission,
which are available for review at www.sec.gov. Forward-looking
statements speak only as of the date they are made. New risks and
uncertainties arise over time, and it is not possible for the
Company to predict those events or how they may affect the Company.
If a change to the events and circumstances reflected in the
Company's forward-looking statements occurs, the Company's
business, financial condition and operating results may vary
materially from those expressed in the Company's forward-looking
Readers are cautioned not to put undue reliance on
forward-looking statements, and the Company assumes no obligation
and do not intend to update or revise these forward-looking
statements, whether as a result of new information, future events
For further information, please contact:
KCSA Strategic Communications
Allison Soss / Scott Eckstein
View original content to download
SOURCE iSpecimen Inc.